PACAP ameliorates obesity‐induced insulin resistance through FAIM /Rictor/ AKT axis
The FEBS Journal · 2024
DOI: 10.1111/febs.17228 ↗Kurz gefasst
Fachartikel in der Zeitschrift The FEBS Journal, 2024. Verfasst von Jia Feng und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cellular Biology, Institute of Biomedicine, Jinan University, Guangzhou, China. Hauptthemen laut MEDLINE: Insulin Resistance, Obesity, Pituitary Adenylate Cyclase-Activating Polypeptide, Proto-Oncogene Proteins c-akt. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben.
Abstract (Originalsprache)
Obesity and obesity‐related insulin resistance have been a research hotspot. Pituitary adenylate cyclase activating polypeptide (PACAP) has emerged as playing a significant role in energy metabolism, holding promising potential for attenuating insulin resistance. However, the precise mechanism is not fully understood. Palmitic acid and a high‐fat diet (HFD) were used to establish insulin resistance model in Alpha mouse liver 12 cell line and C57BL/6 mice, respectively. Subsequently, we assessed the effects of PACAP both in vivo and in vitro . Lentivirus vectors were used to explore the signaling pathway through which PACAP may ameliorate insulin resistance. PACAP was found to selectively bind to the PACAP type I receptor receptor and ameliorate insulin resistance, which was characterized by increased glycogen synthesis and the suppression of gluconeogenesis in the insulin‐resistant cell model and HFD‐fed mice. These effects were linked to the activation of the Fas apoptotic inhibitory molecule/rapamycin‐insensitive companion of mammalian target of rapamycin/RAC‐alpha serine/threonine‐protein kinase (FAIM/Rictor/AKT) axis. Furthermore, PACAP ameliorated insulin resistance by increasing solute carrier family 2, facilitated glucose transporter members 2/4 and inhibiting gluconeogenesis‐related proteins glucose 6‐phosphatase catalytic subunit 1 and phosphoenolpyruvate carboxykinase 2 expression. Meanwhile, the phosphorylation of hepatic AKT/glycogen synthase kinase 3β was promoted both in vivo and in vitro by PACAP. Additionally, PACAP treatment decreased body weight, food intake and blood glucose levels in obese mice. Our study shows that PACAP ameliorated insulin resistance through the FAIM/Rictor/AKT axis, presenting it as a promising drug candidate for the treatment of obesity‐related insulin resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cellular Biology, Institute of Biomedicine, Jinan University, Guangzhou, China.
- Key Laboratory of Bioengineering Medicine of Guangdong Province, Jinan University, Guangzhou, China.
- The National Demonstration Center for Experimental Education of Life Science and Technology, Jinan University, Guangzhou, China.
- Department of Metabolic and Bariatric Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, China.
Zitieren
APA
Feng, J., Chen, W., Li, S., Fang, Q., Chen, X., Bai, G., Tian, M., Huang, Y., Xu, P., Wang, Z., & Ma, Y. (2024). PACAP ameliorates obesity‐induced insulin resistance through FAIM /Rictor/ AKT axis. The FEBS Journal. https://doi.org/10.1111/febs.17228
Vancouver
Feng J, Chen W, Li S, Fang Q, Chen X, Bai G, et al. PACAP ameliorates obesity‐induced insulin resistance through FAIM /Rictor/ AKT axis. The FEBS Journal. 2024. doi:10.1111/febs.17228
BibTeX
@article{Feng2024,
author = {Feng, Jia and Chen, Wenhui and Li, Shanshan and Fang, Qianchen and Chen, Xingwu and Bai, Ge and Tian, Meng and Huang, Yongmei and Xu, Pei and Wang, Zixian and Ma, Yi},
title = {PACAP ameliorates obesity‐induced insulin resistance through FAIM /Rictor/ AKT axis},
journal = {The FEBS Journal},
year = {2024},
doi = {10.1111/febs.17228}
}
EUVIMED